GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Instituto Rosenbusch SA (BUE:ROSE) » Definitions » Forward PE Ratio

Instituto Rosenbusch (BUE:ROSE) Forward PE Ratio : 0.00 (As of Jun. 29, 2025)


View and export this data going back to . Start your Free Trial

What is Instituto Rosenbusch Forward PE Ratio?

Instituto Rosenbusch's Forward PE Ratio for today is 0.00.

Instituto Rosenbusch's PE Ratio without NRI for today is 0.00.

Instituto Rosenbusch's PE Ratio (TTM) for today is 0.00.


Instituto Rosenbusch Forward PE Ratio Historical Data

The historical data trend for Instituto Rosenbusch's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Instituto Rosenbusch Forward PE Ratio Chart

Instituto Rosenbusch Annual Data
Trend
Forward PE Ratio

Instituto Rosenbusch Quarterly Data
Forward PE Ratio

Competitive Comparison of Instituto Rosenbusch's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Instituto Rosenbusch's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Instituto Rosenbusch's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Instituto Rosenbusch's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Instituto Rosenbusch's Forward PE Ratio falls into.


;
;

Instituto Rosenbusch Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Instituto Rosenbusch  (BUE:ROSE) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Instituto Rosenbusch Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Instituto Rosenbusch's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Instituto Rosenbusch Business Description

Traded in Other Exchanges
N/A
Address
Hipolito Yrigoyen 1628, Buenos Aires, ARG, C1089AAF
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.